Stefan K. Barta, MD, MRCP(UK) underwent medical training at the Johann Wolfgang Goethe University Frankfort, Germany. He completed his internal medicine training at the St. Bartholomew’s and The Royal London Hospital, UK and his hematology-oncology fellowship at the Montefiore Medical Center/Albert-Einstein College of Medicine, Bronx, New York. Previously, Dr Barta led the T-cell lymphoma program at the Fox Chase Cancer Center. He is currently an Associate Professor of Medicine at the University of Pennsylvania, and is in charge of the T Cell Lymphoma Program. His research interests are focused on novel therapies in T-cell and other aggressive lymphomas. He was awarded with an American Society of Clinical Oncology (ASCO) Young Investigator Award in 2010. Since then, he has led and/or developed multiple investigational clinical trials for lymphoma either as study chair, principal investigator or site principal investigator. He serves on the lymphoma committees for the Eastern Cooperative Oncology Group (ECOG-ACRIN) and AIDS Malignancy Consortium (AMC) and is a member of the AMC steering committee. He is reviewer for several oncological journals and is on the editorial board for “Clinical Lymphoma, Myeloma & Leukemia”.
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
The third episode in the series, Dr. María Victoria Mateos and Dr. Alexander Lesokhin discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile
Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL
Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.
Dr Claudio Cerchione summarises highlights from SOHO, SOHO Italy and IMW 2021
In this second episode, Dr. Joshua Richter and Dr. Karthik Ramasamy discuss their views on choosing the best treatment regimen in relapsed/refractory multiple myeloma (RRMM)